Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 10/2013

01-10-2013 | Research Article

Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis

Authors: Z. Song, L. Shao, B. Lin, Y. Zhang

Published in: Clinical and Translational Oncology | Issue 10/2013

Login to get access

Abstract

Objective

This retrospective analysis evaluates the clinical outcomes of extensive-stage small cell lung cancer (SCLC) patients who received second-line chemotherapy after platinum-based first-line chemotherapy, especially focusing on efficacy and toxicity between single-agent and combination chemotherapy.

Methods

We retrospectively reviewed 193 patients who received second-line chemotherapy for extensive-stage SCLC. Patients relapsing or progressing beyond 90 days were defined as sensitive recurrence patients, and below 90 days as refractory recurrence patients. Survival curves were plotted using the Kaplan–Meier method. The Cox proportional hazard model was used for multivariate analysis.

Results

138 patients received combination chemotherapy and 55 received single-agent treatment. The objective response rate (ORR) was 25.4 % in the combination group and 9.1 % in the single-agent group (p = 0.012). The disease control rate (DCR) was 65.2 and 34.5 %, respectively, (p < 0.001). The progression-free survival (PFS) was 3.80 months in the combination group and 2.13 months in the single-agent group (p = 0.001). In the sensitive recurrence group, the median PFS was 3.80 months in combination group and 3.23 months in single-agent group (p = 0.092). In the refractory recurrence group, the median PFS was 2.83 and 1.30 months, respectively (p = 0.001). The grade III/IV toxicity in single-agent group is much lower than the combination group (56.4 vs. 74.6 %, p = 0.013).

Conclusion

Our retrospective data suggest a potential role of prolonging the PFS for combination treatment in extensive-stage SCLC second-line treatment, especially for the refractory recurrence patients, but with more toxicity as compared to single-agent.
Literature
1.
2.
Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539–4544PubMedCrossRef
3.
Riaza SP, Lüchtenborga M, Couplanda VH, Spicer J, Peakec MD, Møller H (2012) Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer 75:280–284CrossRef
4.
Kurup A, Hanna NH (2004) Treatment of small cell lung cancer. Crit Rev Oncol Hematol 52:117–126PubMed
5.
Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91PubMedCrossRef
6.
Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH (2001) Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593–a phase III trial of the Eastern Cooperative oncology Group. J Clin Oncol 19:2114–2122PubMed
7.
Naka N, Kawahara M, Okishio K, Hosoe S, Ogawara M, Atagi S et al (2002) Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer 37:319–323PubMedCrossRef
8.
Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C et al (2010) Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 28:2598–2603PubMedCrossRef
9.
Kakolyris S, Mavroudis D, Tsavaris N, Souglakos J, Tsiafaki P, Kalbakis K et al (2001) Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. Ann Oncol 12:193–197PubMedCrossRef
10.
Owonikoko T, Behera M, Chen ZJ, Bhimani C, Curran WJ, Khuri FR et al (2012) A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol 7:866–872PubMedCrossRef
11.
Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachterset FM et al (2009) Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 27:1836–1843PubMedCrossRef
12.
von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658–667
13.
Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K et al (2008) Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 26:5401–5406PubMedCrossRef
14.
Pallis AG, Agelidou A, Agelaki S, Varthalitis I, Pavlakou G, Gerogianni A et al (2009) Multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer. Lung Cancer 65:187–191PubMedCrossRef
15.
Hirose T, Horichi N, Ohmori T, Ogura K, Hosaka T, Ando K et al (2003) Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung cancer 40:333–338PubMedCrossRef
16.
Kakolyris S, Mavroudis D, Tsavaris N, Souglakos J, Tsiafaki P, Kalbakis K et al (2001) Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. Ann Oncol 12:193–197PubMedCrossRef
17.
Yamamoto N, Tsurutani J, Yoshimura N, Asai G, Moriyama A, Nakagawa K et al (2006) Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res 26:777–781PubMed
18.
Schmittel A, Knödler M, Hortig P, Schulze K, Thiel E, Keilholz U et al (2007) Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 55:109–113PubMedCrossRef
19.
Socinski MA, Raju RN, Neubauer M, Smith DA, Richards DA, Savin M et al (2008) Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial. J Thorac Oncol 3:1308–1316PubMedCrossRef
20.
Garassino MC, Torri V, Michetti G (2011) Lo Dico M, La Verde N, Aglione S, Mancuso A et al Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer 72:378–383PubMedCrossRef
21.
Sundstrom S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S (2005) Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristine (CEV-regimen). Lung Cancer 48:251–261PubMedCrossRef
22.
Kim YH, Goto K, Yoh K, Niho S, Ohmatsu H, Kubota K et al (2008) Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy. Cancer 113:2518–2523PubMedCrossRef
Metadata
Title
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis
Authors
Z. Song
L. Shao
B. Lin
Y. Zhang
Publication date
01-10-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 10/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1013-5

Other articles of this Issue 10/2013

Clinical and Translational Oncology 10/2013 Go to the issue

Brief Research Article

Intimal–medial thickness and carotid arteries lumen in irradiated patients for head and neck cancer: preliminary data of an observational study

Research Article

Expression and prognostic role of c-Myb as a novel cell cycle protein in esophageal squamous cell carcinoma

Educational series - Blue Series

Ependymoma in children: molecular considerations and therapeutic insights

Research Article

Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer

Research Article

Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences

Research Article

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits